Cure Today16h
Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma
The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed ...
MEDIPOST, Inc. Expands U.S. Presence with Key Executive Appointments, advances toward Phase III clinical trial of CARTISTEM® in North America
MEDIPOST, Inc. appoints 5 senior executives as part of the company’s journey to bring its flagship regenerative therapy, CARTISTEM®, to the U.S.
Lost Money on Humacyte, Inc. (HUMA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a ...
Shareholders That Lost Money on Humacyte, Inc. (HUMA) Should Contact Levi & Korsinsky About Pending Class Action - HUMA
THE LAWSUIT: A class action securities lawsuit was filed against Humacyte, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between May 10, ...
manilatimes17h
PolarityBio Announces Interim Enrollment Achieved in SkinTE's Phase III Pivotal Study
PolarityBio, a clinical-stage biotechnology company developing regenerative tissue products, today announced that it has ...
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
New York, New York-- (Newsfile Corp. - December 3, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, ...
中国日报网3h
China seen as fertile land for pharma firms
China's massive consumer base, strengthened intellectual property protection, and enhanced innovation climate are converging ...
Florida medical marijuana operators ready to light up
Florida's medical marijuana industry is about to get much bigger. Click to see how many new licenses are being awarded and what it means for patients and businesses.